Shares of Geron $GERN rose sharply on Monday during early trading following an announcement of its licensing deal with Janssen Pharmaceuticals $JNJ. The deal valued at about $80 million grants Janssen exclusive rights to develop and commercialize products based on Geron�s specialized oligonucleotide backbone chemistry.